Development of a Treatment for Jaw Clefts Using Dental Pulp Stem Cells and Artificial Bone with ORTHOREBIRTH

「For dental pulp stem cells, the Company has had multiple academic institutions and companies assess their potential to provide new treatments in areas such as bone and neurological diseases by determining their suitability for treating diseases. During the previous consolidated fiscal year, the Company entered into joint research agreements with Showa University for bone-related diseases, Gifu Pharmaceutical University for eye-related diseases, and the Tokyo Metropolitan Institute of Medical Science, Nagoya University Hospital and Tokyo Medical and Dental University for cerebral palsy, as well as with Oita University for peripheral nerve paralysis and Nagoya University for spinal cord injuries. It also entered into a joint research and development agreement with ORTHOREBIRTH Co., Ltd. to create a treatment for cleft lip and palate, and a joint commercialisation agreement with Mochida Pharmaceutical Co.,Ltd. for regenerative medicine products for rare and intractable gastrointestinal diseases, including intestinal neuronal dysplasia. Research and development activities are being advanced under each agreement.」

「The Company believes that Revosys, a cotton-like artificial bone graft material held by ORTHOREBIRTH Co., Ltd., can create a new treatment when combined with dental pulp stem cells. The Company therefore entered into a joint research agreement with ORTHOREBIRTH Co., Ltd. and is conducting development activities.」

「During the first quarter cumulative period, we entered into a joint research and development agreement with ORTHOREBIRTH㈱ to create a treatment for cleft lip and palate, and began R&D activities aimed at developing a novel treatment by making maximum use of the dental pulp stem cell therapy platform owned by セルテクノロジー㈱, which became a wholly owned subsidiary in April.」

「To create a new treatment for this disease by combining dental pulp stem cells, which have excellent bone-regeneration capabilities and are an optimal cell source for regenerative medicine for cleft lip and jaw, with Revosis, a cotton-like artificial bone-filling material owned by ORTHOREBIRTH㈱, with which we have a capital and business alliance, we entered into a joint research and development agreement with the company in May 2019 and began development activities through collaboration between the two companies.」